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diagnosed at the time of radical prostatectomy
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Antonio Di Meglio1,2*, Pier Vitale Nuzzo1,2, Francesco Ricci2, Bruno Spina3 and Francesco Boccardo1,2Abstract
Background: Pelvic lymph nodes removed during radical retropubic prostatectomy for prostatic cancer can be found
on pathological examination to harbor various unexpected pathologies. Among these, hematologic neoplasms are not
infrequent. Given their frequently indolent clinical course, such neoplasms would likely have remained undiagnosed
and non-life threatening. Despite this, the case we are reporting describes a rare association between two aggressive
neoplasms, and it will be helpful to clinicians who encounter similar combinations of pathologies.
Case presentation: We report the challenging case of a 56-year-old, caucasian man in whom pathological assessment
of pelvic lymph nodes removed during radical retropubic prostatectomy for a high-grade prostatic neoplasm revealed
Hodgkin lymphoma, which was subsequently classified as stage IV. There are very few published reports of this
combination of pathologies. This situation required a cautious and expert approach to delivering the most appropriate
treatment with the most appropriate timing for both diseases.
Conclusion: This report describes the multidisciplinary clinical approach we followed at our institution. We have also
presented a review of published reports concerning the incidence, histologic type, and management of such
concurrent malignancies.
Keywords: Prostatic neoplasm, Radical prostatectomy, Hodgkin lymphoma, Hematologic neoplasm, Concurrent
malignancies, CD44, Literature reviewBackground
Currently, radical retropubic prostatectomy (RRP) is con-
sidered the gold standard for local treatment of organ-
confined prostate cancer (PCa) [1,2]. Recognizing pelvic
lymph node metastases from PCa during pre-operative as-
sessment can be problematic. Because nodal involvement
is often microscopic and therefore undetectable by using
standard imaging techniques and dimensional and mor-
phologic criteria, metastatic involvement of pelvic nodes
can be overlooked preoperatively; only to be discovered* Correspondence: antonio.dimeglio@rocketmail.com
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unless otherwise stated.unexpectedly by pathologists in the resected specimen
[3,4].
Several incidental findings, other than metastases from
PCa, have been reported in pelvic lymph nodes evaluated
at the time of RRP. These have included nodal metastases
from malignancies arising in another primary site and
non-metastatic disease arising directly from lymphoid tis-
sue (i.e., various types of leukemia/lymphoma).
We describe the case of a patient who underwent sur-
gery for a biopsy-proven high-grade PCa and had an in-
cidental diagnosis of Hodgkin lymphoma (HL) involving
pelvic lymph nodes. We then performed a systematic
search of published reports concerning associations be-
tween PCa and hematologic malignancies (HM) discov-
ered as a result of surgery for the PCa. Although several
cases of concomitant HM and primary PCa have beenral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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for the management of such patients are thus far avail-
able. Moreover, the clinical significance and prognostic




A 56-year-old man was referred to our unit after under-
going RRP and bilateral pelvic lymphadenectomy at an-
other hospital. Pathological examination had confirmed
the initial diagnosis of high-grade adenocarcinoma,
Gleason score 10 (5 + 5), consistent with the findings on
the biopsies performed preoperatively. Additionally, it
had disclosed disease extension to both lobes of the
gland, apex, and seminal vesicles, and focal involvement
of the resection margins (Figure 1).
None of the 30 lymph nodes removed in the proced-
ure contained metastatic cells from the PCa. Rather and
surprisingly, the larger lymph nodes were found toFigure 1 Adenocarcinoma of the prostate, Gleason 10. Hematoxylin an
poorly differentiated adenocarcinoma of the prostate (Gleason score 5 + 5
invasion; and (D) presence of multifocal embolic perineural tumor.contain classic mixed cellularity HL. The malignant
Hodgkin and Reed-Sternberg cells stained positive for
cluster of differentiation (CD) 20, CD30, and CD15.
Additionally, immunohistochemistry was negative for
CD45, CD3, epithelial membrane antigen, and PAX5
(Figure 2).
When the patient was referred to our clinics 1 month
postoperatively, his serum concentration of prostate-
specific antigen (PSA) was 0.34 ng/mL (pre-surgical PSA
had been 6.6 ng/mL).
A staging 18-fluoro-deoxyglucose positron emission
tomography (FDG PET) scan showed nodal disease on
both sides of the diaphragm with enhanced metabolic
activity in the spleen and skeleton (Figure 3A). However,
no tumor invasion was detected on bone marrow biopsy.
A whole-body computed tomography (CT) scan con-
firmed axillary, mediastinal, celiac trunk, and retroperi-
toneal lymphadenopathies and failed to detect any bone
lesions. Because the PET scan was positive at the bone
level, his HL was classified as stage IV according to thed eosin stained photomicrographs (10x magnification) showing: (A)
= 10); (B) disease extension into seminal vesicles; (C) tumor vascular
Figure 2 Infiltration of Hodgkin lymphoma within lymph nodes. Photomicrographs of (A) malignant Hodgkin and Reed-Sternberg cell
showing (B) negative staining for CD45; (C) positive staining for CD30; and (D) positive staining for CD15.
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from PCa could not be completely excluded. The patient
underwent front-line combination chemotherapy with
the EBVD regimen (epirubicin 35 mg/m2; bleomycin
10 mg/m2; vinblastine 6 mg/m2; dacarbazine 375 mg/
m2). A multidisciplinary team of experts, including he-
matologists and radiation oncologists, planned and con-
curred on this approach.
After three cycles of treatment, an interim evaluation
with a FDG PET scan showed no FDG-avid tissue in the
previously positive sites. These data were confirmed by a
whole-body CT scan, which showed shrinkage of previ-
ously enlarged lymph nodes. Thus, there was evidence
that the HL had responded well to chemotherapy; how-
ever, during this time the PSA concentration had further
increased up to 0.96 ng/mL (PSA doubling time
1.92 months). Therefore, anti-androgen therapy with
bicalutamide, 150 mg per day, was initiated. In addition
to providing evidence of HL response to chemotherapy,
the radiologic images also showed interstitial pneumonia,which was considered an adverse effect of bleomycin.
Hence, three more cycles of chemotherapy without bleo-
mycin and with the addition of 40 mg of prednisone daily
on days 1–5 of each cycle were scheduled.
After six cycles of chemotherapy, a FDG PET scan
showed no residual disease (Figure 3B); a whole-body
CT scan confirmed complete disappearance of the
lymphoma lesions and resolution of the interstitial pneu-
monia. PSA was undetectable in his serum. Nevertheless,
because of the adverse prognostic features of his PCa;
namely, the high Gleason score, invasion of seminal vesi-
cles, positive surgical margins, and the increase in PSA
concentrations postoperatively (before commencement
of bicalutamide therapy), on completion of chemother-
apy for HL, the patient was also submitted to pelvic ir-
radiation (60 Gy were delivered in 30 fractions to the
whole pelvis followed by an 18-Gy boost to the prostatic
bed, which required the delivery of eight additional daily
fractions). PSA continued to be undetectable in his
serum up until completion of treatment and thereafter.
Figure 3 FDG PET scan images before and after treatment. (A) Staging FDG PET scan image showing nodal disease on both sides of the
diaphragm with enhanced metabolic activity in the spleen and skeleton. (B) End of treatment: FDG PET image showing no residual disease.
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continued and the patient is being rigorously followed
up with serum PSA checks 3 monthly and whole body
FDG PET/CT scans 6 monthly. At the time of this re-
port, 30 months after this patient’s referral to our clinics,
there is no evidence of either HL recurrence or of PCa
progression (serum PSA remains undetectable).Discussion
We performed a systematic search of the PubMed database
using the MeSH keywords “prostatic neoplasms”, “prosta-
tectomy”, “lymphoma”, and “hematologic neoplasms” and
identified retrospective reviews of a total of over 19,000
specimens (most of which had been obtained from patients
who had undergone RRP). We identified seven studies,
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dental (non-metastatic) lymph node pathology discovered
during RRP that had been performed between 1996 and
2007. The findings of these studies are summarized in
Table 1.
We also identified three case reports of patients who
had been diagnosed with a second malignant hematologic
neoplasm in addition to their PCa. These isolated cases
are also listed in Table 1.
In the evaluated series, the overall incidence of HM
harbored by pelvic lymph nodes removed in the course
of RRP had a range from 0.003% [9] to 1.2% [7]. In the
great majority of these cases, the diagnosis of a HM had
not been suspected preoperatively.
Currently, contrast-enhanced CT scan along with MRI
are the most commonly employed techniques for evalu-
ating nodal disease pre-operatively in patients with PCa.
These imaging techniques are usually reserved for pa-
tients with an intermediate or high risk of extra-
prostatic and/or nodal disease dissemination [16,17].
Evaluation of lymph node metastasis is one of the major
goals of CT scanning in PCa staging. However, such
evaluation is limited by false-positive results and the
paucity of available techniques for identifying lymph
node metastasis [18].
Moreover, unsuspected abnormalities, unrelated to the
known primary PCa, can be revealed during the diagnos-
tic/staging imaging workup. Miller et al. reported dis-
covering a clinically significant coexistent disease by CT
scan in 89/1330 PCa patients (6.7%) who were to
undergo radiation therapy [19].
Elmi et al. retrospectively reviewed 355 initial staging
abdominopelvic CT examinations in patients with PCa
for incidental findings that were unrelated to their pri-
mary disease. These “incidentalomas” were classified as
being of low, moderate, or high importance, depending
on the type of medical or surgical management eventu-
ally required or on their potential to adversely affect
health. Seventy-five potentially significant findings were
noted in 73 patients (20.6% of all patients): most were
renal masses; these were confirmed to be renal cell ma-
lignancies in seven patients (1.97% of all patients). Add-
itionally, lymphadenopathies at sites unlikely to harbor
PCa metastasis were noted in 18 cases, in four of whom
histopathologic examination resulted in a diagnosis of
lymphoma (1.12% of all patients) [20]. Enlarged lymph
nodes were detected in 102 patients; only 18 of these
were in sites uncommonly affected by PCa metastasis
(mainly mesenteric). Accordingly, Coakley et al. suggested
that a diagnosis of lymphoma should be considered in pa-
tients with PCa and imaging findings of mesenteric
lymphadenopathies [21].
He et al. reported a <1% incidence of metastases from
PCa in pelvic lymph nodes [11]. This rate of positivity isunusually low compared with major retrospectively
assessed series reported by Roehl et al. and Daneshmand
et al.: these authors cite an incidence of enlarged lymph
nodes in typical PCa locations in the range of 5.8% [22]
to 12.1% [23] in series of 3478 and 1972 patients, re-
spectively, who had undergone RRP and lymph node
dissection. However, Partin et al. have reported an even
larger series of 5079 cases, considerably more than in ei-
ther Roehl et al. or Daneshmand et al.’s series. These au-
thors reported pathologically confirmed metastatic
involvement by PCa of lymph nodes in 2% of the 5079
lymph node dissections performed [24].
Winstanley et al. have reported other findings apart
from hematolymphoid pathology in enlarged pelvic
nodes in patients undergoing RRP. Most such lymph
nodes findings did not harbor neoplasms but were af-
fected by other pathologies, including sinus histiocytosis,
non-caseating granulomas, and foreign body reactions.
Therefore, pathologists should be aware of these possi-
bilities, to arrive at the correct diagnosis [9].
In the present case, our patient had not undergone any
pre-surgical staging, probably because of his good general
health and young age. In regard to age, Elmi et al. re-
ported that the overall rate of incidental findings is not
significantly different in patients aged <65 versus >65 years.
However, they reported that patients aged more than
65 years have a higher rate of second neoplasms/syn-
chronous malignancies than younger patients [20]. These
findings are not relevant to our patient, who was aged less
than 65 years.
Preexisting co-morbidities can influence treatment
choices in patients with newly diagnosed PCa [25].
Though possible, incidental discovery of life-threatening
conditions that may force clinicians to delay or modify
the scheduled treatment for PCa is rare: imaging overuse
can lead to over-diagnosis of subclinical conditions that
would never become overt during a patient’s lifetime;
this is a worldwide issue [26].
When discovered incidentally, HM are usually at an
extremely early stage, have limited spread, and are
asymptomatic [7,11]. Although our patient was asymp-
tomatic, he had stage IV HL involving lymph nodal
stations on both sides of the diaphragm, as well as extra-
nodal sites (spleen and skeleton). It is extremely rare to
find such advanced disease incidentally. Of the cases
identified by Eisenberger et al. in over 4000 procedures,
none had diffuse and/or bulky disease [8].
Taking together, only six of 89 reported cases of inciden-
tally discovered HM required an aggressive approach.
Most reported patients with incidentally discovered HM
had low-grade follicular non-Hodgkin lymphoma or small
lymphocytic lymphoma/chronic lymphocytic leukemia.
Considering the indolent nature of these conditions and
the associated expected long-term survival, the decision to
Table 1 Published reports of incidental concurrent findings during RRP and lymph node dissections for PCa
Authors and year Number of radical prostatectomies
(Number of lymph node dissections
performed)







Donohue et al. 1996 [5,6] 225 (N.A.) 3 (1.2%) Lymphoma NOS N.A.
Terris et al. 1997 [7] 1092 (all patients) 13 (1.2%) 3 HL Pelvic and abdominal external beam irradiation
1 HCL Aggressive tp NOS
1 CLL No tp
6 SLL No tp
Eisenberger et al. 1999 [8] 4319 (all patients) 10 (0.2%) 8 Lymphocytic lymphoma Single-agent CT
2 FL N.A
Winstanley et al. 2002 [9] 1001 (854) 15 (1.8%) 2 SLL/CLL N.A.
3 neoplastic (0.003%) 1 FL N.A.
12 Non-neoplastic findings1 N.A.
Weir et al. 2003 [10] 6143 (all patients) 18 (0.3%) 18 SLL/CLL N.A.
He et al. 2007 [11] 1500 (1150) 13 (1.13%) 9 SLL/CLL N.A.
3 MZL N.A.
1 MCL Aggressive CT NOS









Isolated case reports Encountered Hematolymphoid malignancy Treatment required for
hematologic malignancy
Carson H et al. 1996 [13] 1 SLL/CLL N.A
Mydlo et al. 2001 [14] 1 lymphoma NOS N.A
Drinis et al. 2009 [15] 1 SLL/CLL No tp
Abbreviations used: NOS not otherwise specified, tp therapy, N.A. not available, CT chemotherapy, HL Hodgkin lymphom, HCL hairy cell leukemia, CLL chronic lymphocytic leukemia, SLL small lymphocytic lymphoma,
MZL marginal zone lymphoma, MCL mantle cell lymphoma.
1Including sinus histiocytosis, non-caseating granulomas, foreign body reactions.
2Prostate and pelvic lymph nodes involved as part of a systemic disease.
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related complications occurred was made in the majority
of patients reported [27].
No clinical management algorithms have yet been de-
fined for synchronous occurrence of PCa and HL; the
impact of such a double diagnosis on clinical outcome is
unknown. Most authors suggest to treat the more ag-
gressive condition first, thus improving the overall status
of the patient and facilitating a better response of the
second disease to therapy [28]. In our case, treatment
decisions were jointly made by a panel of experts. Be-
cause HL appeared to be both the more aggressive of
the two conditions and the disease in which cure was
more likely to be achieved, combination chemotherapy
with the EBVD regimen was initiated as soon as the pa-
tient had recovered from his surgery: complete remis-
sion of the disease was achieved within a few months.
To avoid any interference with the treatment for his
lymphoma, our panel of experts decided to postpone
pelvic radiotherapy, even though it was robustly indi-
cated in view of the locally advanced stage of PCa andFigure 4 Seminal vesicle infiltration by adenocarcinoma of the prosta
eosin stained photomicrographs showing left seminal vesicle infiltration by
magnification, respectively) (B,D) Photomicrographs showing positive CD4
adenocarcinoma of the prostate (10× and 40× magnification, respectively).microscopic residual disease. The decision to postpone
this treatment was supported by the prompt PSA re-
sponse to the anti-androgen therapy initiated after the
first two chemotherapy cycles. Though no randomized
studies have demonstrated clear superiority for immedi-
ate treatment of biochemical recurrence with radiation
or hormonal therapy, several retrospective studies have
shown that anti-androgen therapy prolongs time to me-
tastasis and probably PCa-specific survival [29,30].
Despite the adverse histologic features and high Glea-
son score of our patient’s PCa, he has had no evidence
of metastatic disease and no increase in PSA since com-
pleting pelvic radiotherapy.
As already mentioned, it is not clear yet whether the
co-existence of a malignant lymphoma can alter per se
the natural history of PCa.
Drinis et al. have raised the intriguing possibility that
lymphomas could potentially protect against PCa pro-
gression. According to these authors, such protection
could result from the over-expression of circulating trans-
membrane molecule CD44 in leukemia and lymphomate (Hematoxylin/Eosin and CD44 staining). (A,C) Hematoxylin and
poorly differentiated adenocarcinoma of the prostate (10× and 40×
4 staining of left seminal vesicle and negative staining CD44 staining of
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suppressor function of CD44 in lymphomas; silencing of
CD44 expression may facilitate lymphoma genesis [31]. In
contrast, circulating concentrations of this protein appear
to be decreased in advanced and metastatic PCa, appar-
ently contributing to tumor progression [32,33].
Gao et al. have also suggested that CD44 is a “meta-
static suppressor gene” in PCa. [34-36]. The biological
role of CD44 might not be identical in all organs and tu-
mors. In tissues that do not normally express CD44, its
acquired expression probably correlates with an adverse
outcome, the CD44 having growth- and metastasis-
promoting actions [37-39].
In light of the above data, we performed CD44 immu-
nostaining on the surgical specimens obtained from our
patient during prostatectomy and lymph node dissection
(Figure 4). The normal prostatic tissue stained positive
for CD44, whereas the PCa tissue did not. The peri-
tumoral stroma, seminal vesicles, and sites of perineural
invasion were mildly CD44 positive. Lymph nodes in-
volved by lymphoma also stained positive for CD44.
These findings support the theory that CD44 is
expressed by normal prostatic epithelium and that cap-
acity for expression is lost during the alterations in
structural differentiation that occur in the course of the
transition to neoplastic tissue. Whether CD44 might be
a prognostic marker indicating the malignant potential
of neoplasm would be difficult to determine because a
standard histologic scoring system that includes CD44
assay would be problematic because of the heterogeneity
and available isoforms of this receptor [40]. Additonally,
the interaction between CD44 expression by lymphoma
cells and PCa cells remains unclear; further investigation
is needed to assign a definite role to this transmembrane
protein [41,42].Conclusions
Apart from some speculations, we are not able to take a
definitive stance about how the concurrent presence of a
HM may affect or interfere with the natural history of
PCa. What we can confidently state is that, in the
present patient, the concurrent presence of a poor-risk
PCa not only did not hamper treatment of the unex-
pected and newly diagnosed advanced-stage HL, but did
not even hinder achievement of complete remission of
the latter and long-term relapse-free survival.Consent
Written informed consent was obtained from the patient
for publication of this case report and the accompanying
images. A copy of the written consent is available for re-
view by the Editor-in-Chief of this journal.Abbreviations
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